Agios Pharmaceuticals (AGIO) Capital Expenditures (2012 - 2026)

Agios Pharmaceuticals has reported Capital Expenditures for 15 years, with the latest figure at $668000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 202.26% year-over-year to $668000.0; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (up 149.9% YoY), and the FY2025 full-year result was $4.3 million, up 156.14% from the prior year.
• Capital Expenditures for Q1 2026 stood at $668000.0, down from $1.1 million in the prior quarter.
• The five-year high for Capital Expenditures was $4.8 million in Q3 2022, with the low at -$1.5 million in Q2 2022.
• Historically, Capital Expenditures has averaged $725312.5 across 5 years, with a median of $543500.0 in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 713.81% — and 2023, when it sank 728.32%.
• Agios Pharmaceuticals' Capital Expenditures stood at $113000.0 in 2022, then slumped by 728.32% to -$710000.0 in 2023, then surged by 236.2% to $967000.0 in 2024, then climbed by 15.82% to $1.1 million in 2025, then tumbled by 40.36% to $668000.0 in 2026.
• The last three Capital Expenditures figures came in at $668000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.